Last updated on March 2019

Strict IGF-1 Control in Acromegaly

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Acromegaly
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Adult patients (at least 18 years old) with confirmed acromegaly who have been on a stable dose of SSA monotherapy, or combination therapy with sub-optimal dose of pegvisomant for at least 6 months and whose IGF-I levels are persistently but modestly (1.0 ULN< [IGF1 serum level] > 1.3 ULN) elevated will be included.

Exclusion Criteria:

  • Visual field loss or optic chiasmal compression or pituitary tumors within 3 mm from the chiasm will not be included
  • Cranial nerve palsies or intracranial hypertension requiring tumour decompression surgery
  • Clinically significant hepatic disease and/or elevated liver enzymes (ALT, AST > 3 x ULN)
  • Patients who have received pituitary surgery within one year prior to screening visit
  • Patients who have received radiation therapy within one year prior to screening visit
  • History of hypersensitivity to any components of Pegvisomant
  • Inability to fully comprehend the nature of the study or cooperate with study procedures
  • Pregnant / lactating women and subjects refusing to use adequate contraception to prevent pregnancy during the study.
  • Subjects unwilling or unable to self-administer medication on a daily basis
  • Known or suspected alcohol / drug abuse
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that could increase the risk associated with trial participation

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.